debrisoquin has been researched along with phenformin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (71.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Commandeur, JN; Funae, Y; Hiroi, T; ter Laak, AM; Venhorst, J; Vermeulen, NP | 1 |
| Arastoo, M; Coxon, GD; Furman, BL; Harvey, AL; Kennedy, AR; McTavish, J; Mooney, MH; Tettey, JM; Waigh, RD | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Park, BK | 1 |
| Evans, DA | 1 |
| Woolhouse, NM | 1 |
| Eichelbaum, M; Idle, JR; Oates, NS; Smith, RL; Woolhouse, NM | 1 |
| Idle, JR; Oates, NS; Shah, RR; Smith, RL | 1 |
| Alvan, G; Bertilsson, L; Sawe, J; Sjöqvist, F; Wiholm, BE | 1 |
| Eichelbaum, M | 2 |
| Boobis, AR; Davies, DS; Kahn, GC; Murray, S; Robertz, GM | 1 |
| Al-Dabbagh, SG; Idle, JR; Küpfer, A; Ritchie, JC; Smith, RL | 1 |
2 review(s) available for debrisoquin and phenformin
| Article | Year |
|---|---|
Ethnic differences in reactions to drugs and xenobiotics. Therapy.
Topics: Acetylation; Debrisoquin; Drug Interactions; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Hydroxylation; Mass Screening; Methyltransferases; Pharmaceutical Preparations; Pharmacogenetics; Phenformin; Polymorphism, Genetic; Sparteine | 1986 |
[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
Topics: Adrenergic beta-Antagonists; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Mephenytoin; Oxidation-Reduction; Perhexiline; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenotype; Phenytoin; Polymorphism, Genetic; Receptors, Drug; Sparteine | 1983 |
12 other study(ies) available for debrisoquin and phenformin
| Article | Year |
|---|---|
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Topics: Alcohol Oxidoreductases; Amino Acid Sequence; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Coumarins; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Enzyme Inhibitors; Humans; Isoenzymes; Kinetics; Ligands; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Protein Binding; Quinidine; Quinine; Rabbits; Rats; Sequence Homology, Amino Acid; Sparteine; Species Specificity | 2003 |
Benzylguanidines and other galegine analogues inducing weight loss in mice.
Topics: Animals; Anti-Obesity Agents; Benzyl Compounds; Dietary Fats; Guanidines; Male; Mice; Mice, Inbred BALB C; Mice, Obese; Microsomes, Liver; Weight Loss | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Metabolic basis of adverse drug reactions.
Topics: Acetaminophen; Acetylation; Adrenergic beta-Antagonists; Adult; Age Factors; Child; Debrisoquin; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Enzyme Inhibitors; Humans; Perhexiline; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenotype; Polymorphism, Genetic; Succinylcholine | 1986 |
The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
Topics: Debrisoquin; Ethnicity; Ghana; Heterozygote; Homozygote; Humans; Isoquinolines; Microsomes, Liver; Nortriptyline; Oxidation-Reduction; Phenformin; Polymorphism, Genetic; Sparteine | 1986 |
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
Topics: Administration, Oral; Adolescent; Adult; Debrisoquin; Female; Ghana; Humans; Isoquinolines; Kinetics; Male; Middle Aged; Phenformin; Phenotype; Sparteine; White People | 1985 |
Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation.
Topics: Acidosis; Aged; Debrisoquin; Female; Humans; Isoquinolines; Lactates; Middle Aged; Phenformin; Phenotype | 1981 |
Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin.
Topics: Acidosis; Debrisoquin; Humans; Hydroxylation; Isoquinolines; Phenformin | 1981 |
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Topics: Antipyrine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Guanidines; Humans; Isoquinolines; Microsomes, Liver; Mixed Function Oxygenases; Phenformin; Sparteine; Substrate Specificity | 1983 |
Polymorphic drug oxidation in humans.
Topics: Cytochrome b Group; Cytochrome P-450 Enzyme System; Cytochromes b5; Debrisoquin; Humans; Mephenytoin; Microsomes, Liver; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenytoin; Polymorphism, Genetic; Sparteine; Tolbutamide | 1984 |
Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
Topics: Animals; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Hydroxylation; In Vitro Techniques; Isoquinolines; Kinetics; Male; Metiamide; Microsomes, Liver; Phenformin; Protein Binding; Rats; Rats, Inbred Strains; Sparteine; Spectrophotometry | 1982 |